Telbivudine use in a patient affected by occult hepatitis B virus and B-cell non-Hodgkin lymphoma.
Arturo
A
Montineri
Luciano
L
Nigro
Annalisa
A
Chiarenza
Licia
L
Larocca
Rosario
R
La Rosa
Carmelo
C
Iacobello
Francesco
F
Di Raimondo
Filippo
F
Fatuzzo
D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000494:pharmacology; D014408:Biomarkers, Tumor / Q000097:blood; D003520:Cyclophosphamide / Q000008:administration & dosage; D004247:DNA / Q000378:metabolism; D006509:Hepatitis B / Q000150:complications* / Q000188:drug therapy*; D006515:Hepatitis B virus / Q000378:metabolism*; D006801:Humans; D016393:Lymphoma, B-Cell / Q000150:complications / Q000188:drug therapy* / Q000821:virology*; D008297:Male; D008875:Middle Aged; D009705:Nucleosides / Q000494:pharmacology*; D011239:Prednisolone / Q000008:administration & dosage; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000096:biosynthesis; D011744:Pyrimidinones / Q000494:pharmacology*; D000069283:Rituximab; D000077712:Telbivudine; D013936:Thymidine / Q000031:analogs & derivatives; D014750:Vincristine / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000998:Antiviral Agents; D014408:Biomarkers, Tumor; D009705:Nucleosides; D019253:Proto-Oncogene Proteins c-bcl-2; D011744:Pyrimidinones; D000077712:Telbivudine; D000069283:Rituximab; D014750:Vincristine; D003520:Cyclophosphamide; D004247:DNA; D011239:Prednisolone; D013936:Thymidine